Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau.

TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs.

By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases.

Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective transfection mechanism to elicit a potent and targeted immune response previously unseen.

THERAVECTYS

Christian Brechot

This department focuses on the research, development, and implementation of vaccine projects.

THERAVECTYS

Org chart

Teams

Vaccine Development

Offices